Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center: a Randomized Controlled Study

Beni-Suef University1 site in 1 country64 target enrollmentJanuary 1, 2021

ConditionsVentilation Acquired Pneumonia

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Ventilation Acquired Pneumonia
Sponsor: Beni-Suef University
Enrollment: 64
Locations: 1
Primary Endpoint: Antimicrobial susceptibility
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this clinical trial is to determine the most effective empirical therapy of antibiotics for better ventilator-associated pneumonia control. The main question it aims to answer is:

• Which is better for clinical response single or combination empiric antibiotic therapies ?

Registry

clinicaltrials.gov

Start Date

January 1, 2021

End Date

January 1, 2022

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Beni-Suef University

Responsible Party

Principal Investigator

Hasnaa Osama

Beni-Suef University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Antimicrobial susceptibility

Time Frame: 7 days

Antimicrobial susceptibility was assessed through Kirby-Bauer's disc diffusion method (DD), Minimal Inhibitory Concentration (MIC) using the automated VITEK 2 compact system (bioMérieux, France), and the Ameri-Ziaei Double Antibiotic Synergism Test (AZDAST). Interpretation of DD and MIC results followed CLSI guidelines.